These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2227772)

  • 21. [Under FDA scrutiny: 19 drugs monitored for safety concerns].
    Sabourin G
    Perspect Infirm; 2010; 7(2):44-5. PubMed ID: 21744604
    [No Abstract]   [Full Text] [Related]  

  • 22. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethical considerations in studying drug safety--the Institute of Medicine report.
    Mello MM; Goodman SN; Faden RR
    N Engl J Med; 2012 Sep; 367(10):959-64. PubMed ID: 22913661
    [No Abstract]   [Full Text] [Related]  

  • 24. Pilot projects to stimulate adverse drug reaction reporting.
    Fincham JE
    J Clin Pharm Ther; 1987 Aug; 12(4):243-7. PubMed ID: 3624325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Congress responds to the IOM drug safety report--in full.
    Psaty BM; Korn D
    JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
    [No Abstract]   [Full Text] [Related]  

  • 26. The FDA Sentinel Initiative - An Evolving National Resource.
    Platt R; Brown JS; Robb M; McClellan M; Ball R; Nguyen MD; Sherman RE
    N Engl J Med; 2018 Nov; 379(22):2091-2093. PubMed ID: 30485777
    [No Abstract]   [Full Text] [Related]  

  • 27. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications: introduction.
    Shane R
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S2-3. PubMed ID: 19966076
    [No Abstract]   [Full Text] [Related]  

  • 28. IOM advises FDA on ethics in postmarket safety trials.
    Kuehn BM
    JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
    [No Abstract]   [Full Text] [Related]  

  • 29. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 30. US consumer group criticizes proposal to allow drug makers to challenge safety information.
    McCarthy M
    BMJ; 2015 Mar; 350():h1514. PubMed ID: 25784706
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug safety, pharmacoepidemiology, and regulatory decision making.
    Nelson RC
    Drug Intell Clin Pharm; 1988 Apr; 22(4):336-44. PubMed ID: 3371198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
    Psaty BM; Meslin EM; Breckenridge A
    JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
    [No Abstract]   [Full Text] [Related]  

  • 33. Legal perspectives in causality assessment.
    Freilich WB
    Drug Inf J; 1984; 18(3-4):211-7. PubMed ID: 10268552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Food and Drug Administration algorithm. Special workshop--regulatory.
    Turner WM
    Drug Inf J; 1984; 18(3-4):259-66. PubMed ID: 10268553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
    Cheng CM; Shin J; Guglielmo BJ
    JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
    [No Abstract]   [Full Text] [Related]  

  • 36. The importance of postmarketing drug surveillance.
    Smart AJ; Walters L
    S Afr Med J; 1992 Dec; 82(6):383-4. PubMed ID: 1465681
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 39. Of education and public policy: Aducanumab.
    Lundebjerg NE; Hollmann PA; Supiano MA
    J Am Geriatr Soc; 2022 Jan; 70(1):81-84. PubMed ID: 34674219
    [No Abstract]   [Full Text] [Related]  

  • 40. How the FDA handles GI drug safety.
    Lewis JH
    Am J Gastroenterol; 2012 Aug; 107(8):1264; author reply 1264-5. PubMed ID: 22859005
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.